Pimavanserin 34 mg at Bedtime for the Treatment of Insomnia in 6 Veterans With Posttraumatic Stress Disorder

References (18)

1. Neylan TC, Marmar CR, Metzler TJ, et al. Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry. 1998;155(7):929–933. PubMed CrossRef
2. Larsen SE, Fleming CJE, Resick PA. Residual symptoms following empirically supported treatment for PTSD. Psychol Trauma. 2019;11(2):207–215. PubMed CrossRef
3. Krystal JH, Davis LL, Neylan TC, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82(7):e51–e59. PubMed CrossRef
4. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540. PubMed CrossRef
5. Patel N, LeWitt P, Neikrug AB, et al. Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis. Clin Neuropharmacol. 2018;41(6):210–215. PubMed CrossRef
6. Jha MK, Fava M, Freeman MP, et al. Effect of adjunctive pimavanserin on sleep/wakefulness in patients with major depressive disorder: secondary analysis from CLARITY. J Clin Psychiatry. 2020;82(1):20m13425. PubMed CrossRef
7. Ancoli-Israel S, Vanover KE, Weiner DM, et al. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med. 2011;12(2):134–141. PubMed CrossRef
8. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29(9):1795–1809. PubMed CrossRef
9. Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. Psychophysiology. 2007;44(4):660–669. PubMed CrossRef
10. Pimavanserin for insomnia in veterans with posttraumatic stress disorder (PIP). ClinicalTrials.gov identifier: NCT04188392. Updated August 31, 2022. https://www.clinicaltrials.gov/study/NCT04188392?cond=pimavanserin%20insomnia&rank=2
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Publishing Inc; 2013.
12. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. PubMed CrossRef
13. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379–1391. PubMed CrossRef
14. Toussaint M, Luthringer R, Schaltenbrand N, et al. First-night effect in normal subjects and psychiatric inpatients. Sleep. 1995;18(6):463–469. PubMed CrossRef
15. Berry RBBR, Gamaldo CE, Hardling SM, et al. The AASM Manual for the Scoring of Sleep and Associated Events. Rules, Terminology and Technical Specifications. American Academy of Sleep Medicine; 2012.
16. Ancoli-Israel S, Martin JL, Blackwell T, et al. The SBSM Guide to Actigraphy Monitoring: Clinical and Research Applications. Behav Sleep Med. 2015;13(suppl 1):S4–S38. PubMed CrossRef
17. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. PubMed CrossRef
18. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef